STAT+: Moderna to pay Roivant up to $2.25 billion to sett...

What’s Happening

Listen up: A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Biotech Biotech STAT Plus: Prime Medicine to seek approval for gene-editing treatment after two-patient trial By Jason Mast The Readout The Readout STAT Plus: CMS wants more drugmakers to join Medicaid most-favored nations pilot By Elaine Chen Biotech Biotech STAT Plus: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says By Adam Feuerstein The Readout The Readout STAT Plus: A Merck cancer drug to watch By Meghana Keshavan Biotech Biotech STAT Plus: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA By Adam Feuerstein STAT Plus: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says By Adam Feuerstein STAT Plus: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad By Lizzy Lawrence and John Wilkerson STAT Plus: A rare disease drug was approvable, then it wasn’t. (and honestly, same)

Inside a surprise rejection By Adam Feuerstein STAT Plus: Brain implants: Whats standing in the way of pivotal trials, FDA approval By O.

Why This Matters

This is the kind of health news that affects everyday decisions.

Health experts are weighing in on what this means for people.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

How do you feel about this development?